查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496019

全球药用辅料市场：2024-2029 年预测

Global Pharmaceutical Excipients Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 126 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

药用辅料市场预计将从2022年的69.17亿美元增至2029年的128.22亿美元，预测期内复合年增长率为9.23%。

赋形剂是药理学上的休眠物质，与动态原料药一起使用，可简化药物生产并有助于润滑性、流动性、劣化和味道。它还具有抗菌作用并促进镇静剂的生理同化。製药工业使用的赋形剂包括填充剂、粘合剂、油、香料、甜味剂、螯合剂、溶剂和助溶剂。为了提供物理和化学稳定的散装剂量配方，药厂严重依赖药用辅料。

全球广泛使用的药物剂型包括锭剂、胶囊、外用乳膏剂和凝胶剂、植入、口服製剂、眼药水、注射剂、吸入剂、经皮吸收贴片、含片、栓剂等。药物赋形剂在这些药物製剂中用于辅助加工、增加原料药的体积和体积，并确保、支持和增加最终产品中剂型的稳定性。

癌症、急性呼吸道疾病、心臟病、糖尿病和其他慢性疾病是全球死亡率增加的主要驱动因素。仅在美国，十分之六的人经常患有慢性疾病，需要持续定期服药。根据国际糖尿病联盟（IDF）的数据，2019年约有4.63亿人（20-79岁的成年人）患有糖尿病，预计到2045年这一数字将增加至7亿。

市场驱动因素：

  • 不断增加的研发（R＆D）预计将推动药用辅料市场的发展。

随着药物配方研究的不断深入和进步，多功能赋形剂被用来改善生产过程和药物品质。赋形剂透过提高治疗的依从性和可行性，在药厂的持续强化中发挥关键作用。

製药业对研发的日益关注预计将对药用辅料产业产生重大影响。这些惰性物质可提高药物稳定性和溶解度，并可用于药物传递形式。它们影响生物有效性、排放曲线和动态药物稳健性，并在药物进步中发挥关键作用。先进的鸦片类药物递送框架（例如奈米颗粒和脂质体）通常需要专门的赋形剂。

FDA 和 EMA 等政府机构不断升级药品监管标准指南和基准，推动对辅料的需求以满足最新措施。根据特定患者需求和恢復区域定製药物配方非常重要。随着製药公司致力于全面的研究和开发，对药用辅料的需求遍及世界各地，生产商看到未来几年有更多的机会供应更广泛的地区。

  • 慢性病的增加预计将推动药用辅料市场的成长。

学名药产业的成长是由慢性病的增加和辅料的改进所推动的，这是药品市场成长的关键。心血管疾病、糖尿病、癌症和慢性呼吸道疾病等主要慢性疾病的增加刺激了对各种治疗方案的需求。

製药公司正在创造创新的药物配方来满足要求，以及新的给药框架，以提高适用性和有效性，同时保持患者的舒适度和依从性。这些药物通常涉及复杂的治疗方案，并需要药用辅料来提高药物稳定性、控制药物释放速率并提高生物有效性。持续释放、标靶递送至特定组织以及克服溶解度和吸收问题需要专门的药物递送系统。

药物赋形剂也用于製造患者友善的剂型，例如缓释片和方便的口服製剂。个人化医疗和生技药品等治疗方法的创新通常需要专门的赋形剂来确保稳定性和有效性。旨在改善慢性病有效治疗方法机会的政府措施和医疗保健政策可能会促进药用辅料市场的成长。

市场限制因素：

  • 製造新辅料所需的成本和时间可能会阻碍市场成长。

药用辅料需要在生产现场接受监管机构的强制测试。由于业界缺乏辅料核准和製造的具体指南，因此与辅料相关的研究和开发倡议迫在眉睫。如果新药核准失败，辅料也会失败，即使与辅料无关。此外，赋形剂的製造非常耗时且成本高。

主要进展

  • 2023 年 10 月 - 路博润生命科学健康公司以其创新技术 Apisolex™ 聚合物增溶赋形剂荣获巴塞隆纳 CPhI 成品配方奖。该奖项由 The Medicine Maker 认可，旨在表彰来自 12 个创新类别的 180 多个参赛作品中的突破性创新。 Apisolex(TM) 聚合物是基于聚（氨基酸）的赋形剂，是 20 多年来第一种肠胃外溶解度增强赋形剂，可将疏水性原料药的溶解度提高高达 50,000 倍让我来做。
  • 2023 年 10 月 - 科莱恩医疗保健在巴塞隆纳 CPHI 上展示了一系列新的赋形剂，可提高原料药配方的稳定性和溶解度。该公司正在推出三种新的 VitiPure® 赋形剂，可用于各种 API 配方和给药途径，包括 mRNA 疫苗和生物製药等敏感配方。科莱恩医疗保健是一家辅料一站式解决方案提供商，为独特的应用提供从标准到高纯度等级的灵活配方。
  • 2023 年 10 月 - 罗盖特在其湿敏药物和营养原料食品产品组合中增加了三种新的辅料等级。这些等级，包括部分预胶化淀粉 Lycatab CT-LM、Microcel 103 SD 和 Microcel 113 SD，是具有独特稳定和防潮效果的结晶纤维素。这些成分旨在帮助製药商优化药物输送，无论製造方法或配方类型如何。罗盖特的防潮特性包含一系列全面的低水分活度 (Aw) 赋形剂，以促进涉及对水分敏感的活性成分的应用中的有效药物输送。
  • 2022 年 7 月 - 全球製药和食品赋形剂解决方案领导者 DFE Pharma 透过推出 Lactohale® 400 扩大了其干粉吸入 (DPI) 产品组合。这种新等级可以客製化以满足特定製药公司的需求，并且是与负责人合作开发的，以确保患者获得正确的结果。 DFE Pharma 全面的乳糖辅料产品组合旨在为市场上所有类型的吸入药物提供合适的特性。 Lactohale(R) 400 是一种研磨的无水乳糖等级，适用于需要良好流动和絮凝性能的 DPI 应用。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球药用辅料市场：依辅料类型

  • 介绍
  • 聚合物
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 酒精
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 醣类
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 矿物
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球药用辅料市场：按製剂类型

  • 介绍
  • 口服
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 外用
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胃肠外的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章全球药用辅料市场：依功能分类

  • 介绍
  • 被覆剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 调味剂/甜味剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 润滑剂和润滑剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 着色剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 乳化剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 缓衝剂
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球药用辅料市场：依分销管道分类

  • 介绍
  • 在线的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 离线
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第九章全球药用辅料市场：按地区

  • 介绍
  • 北美洲
    • 按添加剂类型
    • 按处方类型
    • 按功能分类
    • 按分销管道
    • 按国家/地区
  • 南美洲
    • 按添加剂类型
    • 按处方类型
    • 按功能分类
    • 按分销管道
    • 按国家/地区
  • 欧洲
    • 按添加剂类型
    • 按处方类型
    • 按功能分类
    • 按分销管道
    • 按国家/地区
  • 中东/非洲
    • 按添加剂类型
    • 按处方类型
    • 按功能分类
    • 按分销管道
    • 按国家/地区
  • 亚太地区
    • 按添加剂类型
    • 按处方类型
    • 按功能分类
    • 按分销管道
    • 按国家/地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • Ashland Global Holdings
  • DuPont
  • BASF SE
  • Roquette Feres
  • Evonik Industries AG
  • Croda International
  • Associated British Foods
  • Archer Daniels Midland Company
  • Lubrizol Corporation
简介目录
Product Code: KSI061611832

The global pharmaceutical excipients market is projected to witness a CAGR of 9.23% during the forecast period to reach a total market size of US$12.822 billion by 2029, increasing from US$6.917 billion in 2022.

Excipients are pharmacologically dormant substances included in conjunction with the dynamic medicate substance to streamline the production of the drug item and help in lubricity, flowability, deterioration, and taste. They may bestow a few shapes of antimicrobial work and additionally encourage the physiological assimilation of the sedate. A few of the excipients utilized in pharmaceutical industries include fillers, binders, oils, flavoring specialists, sweeteners, chelating operators, solvents, co-solvents, etc. To supply the bulk dose formulations steady in physical and chemical, the formulator is profoundly subordinate to the pharmaceutical excipients.

A few pharmaceutical dosage forms that are easily and widely available and utilized globally are tablets, capsules, topical creams and gels, implants, oral dosage, eye drops, injectable products, inhalers, transdermal patches, lozenges, and suppositories. Pharmaceutical excipients are utilized in these pharmaceutical medication formulations to help the processing, providing bulk or volume to API, and securing, supporting, or incrementing the stability of the dosage forms in the final product.

Cancer, acute respiratory disease, heart stroke, diabetes, and other chronic diseases are the major driving factors of rising mortality in the world. Inside the United States alone, six out of ten individuals endure chronic illness regularly and require persistent and regular pharmaceutical medicines regime intake. As per the International Diabetes Federation (IDF), around 463 million people (20-79 years adults) were living with diabetes in 2019, and by 2045, the number is expected to increase to 700 million, showing a rise in demand for medicines in turn boosting the Pharmaceutical Excipients market growth.

Market Drivers:

  • Increasing research and development (R&D) is expected to boost the pharmaceutical excipients market.

Expanded investigations and advancements in pharmaceutical formulations utilize multi-functional excipients to progress the process of production and medication quality. Excipients play a significant part in helping pharmaceutical manufacturers in giving progress persistent bolster by improving compliance and treatment viability.

The pharmaceutical industry's rising attention on R&D is anticipated to emphatically affect the industry for pharmaceutical excipients. These inert substances improve medicate steadiness and solvency and help in medicate delivery forms. They play a vital part in medication advancement, influencing the bioavailability, discharge profile, and solidness of dynamic drugs. R&D endeavors drive advancement in pharmaceutical medication details, with progressed sedate conveyance frameworks such as nanoparticles and liposomes frequently requiring specialized excipients.

Administrative bodies just like the FDA and EMA continuously upgrade regulations standard guidelines and benchmarks for pharmaceutical items, driving the requirement for excipients that meet the most recent measures. Customization of medication formulations on the basis of particular patient needs and restorative zones are significant. As pharmaceutical companies contribute to R&D all-inclusive, the request for pharmaceutical excipients is likely to extend around the world, with producers seeing expanded openings to supply to broader regions in the years ahead.

  • A rise in chronic diseases is expected to surge the pharmaceutical excipients market growth.

The rising generics medicine industry is driven by the rise in chronic illnesses and the improvement of excipients, which are a key figure within the pharmaceutical market growth. The rise in major chronic disorders, like cardiovascular, diabetes, cancer, and chronic respiratory conditions, is fueling the demand for different treatment alternatives.

Pharmaceutical companies are creating innovative medication formulations for fulfilling the requirement as well as emerging delivery frameworks to progress adequacy and effectiveness with the comfort and compliance of patients. These medicines frequently include complex regimens, requiring pharmaceutical excipients to improve the stability of the medicine, control release rates of the drug, and enhance its bioavailability. Specialized drug delivery systems are necessary for sustained release, targeted delivery to specific tissues, and overcoming solubility and absorption issues.

Pharmaceutical excipients can also be used to create patient-friendly dosage forms, such as extended-release tablets or convenient oral formulations. Innovations in therapeutic approaches, such as personalized medicine and biologics, often require specialized excipients for stability and effectiveness. Government initiatives and healthcare policies aimed at improving access to effective treatments for chronic diseases may contribute to the pharmaceutical excipient market growth.

Market Restraints:

  • Cost and time consumed in creating new excipients could hinder the market growth.

Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. The industry lacks separate guidelines for approval and manufacturing of excipients is impending R&D initiatives related to excipients. If a new drug approval fails, the excipient also fails, even if it is not related to the excipient. Moreover, a considerable amount of time and cost goes into creating an excipient.

Key Developments:

  • October 2023- Lubrizol Life Science Health won the Finished Formulation Award at CPhI Barcelona for its innovative technology, Apisolex(TM) Polymer solubilizing excipient. The award, which was recognized by The Medicine Maker, was awarded to a breakthrough innovation among over 180 entries in 12 innovation categories. The winners were announced at a networking reception with over 500 attendees.Apisolex(TM) Polymer, a poly(amino acid)-based excipient, is the first solubility-enhancing excipient for parenteral use in over 20 years, enhancing hydrophobic API solubility by up to 50,000-fold.
  • October 2023- Clariant Health Care launched a new range of excipients at CPHI Barcelona to improve the stability and solubility of active pharmaceutical ingredient (API) formulations. The company will unveil three new VitiPure(R) excipients, which can be used for various API formulations and administration routes, including sensitive ones like mRNA vaccines and biological medications. Clariant Health Care is a one-stop shop solution provider of excipients, offering a range from standard to highly purified grades for unique application-specific formulation flexibility.
  • October 2023- Roquette added three new excipient grades for moisture-sensitive active pharmaceutical and nutraceutical ingredients to its portfolio. These grades, including partially pregelatinized starch Lycatab CT-LM, Microcel 103 SD, and Microcel 113 SD, are microcrystalline cellulose with unique stabilizing and moisture-protective benefits. These ingredients are designed to help pharmaceutical manufacturers optimize drug delivery, regardless of production method or formulation type. Roquette's moisture protection profile incorporated a comprehensive variety of low water activity (Aw) excipients, which bolster effective drug advancement in applications including moisture-sensitive active ingredients.
  • July 2022- DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, expanded its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale(R) 400. This new grade can be customized to meet specific pharmaceutical company needs and developed jointly with formulators to ensure the right outcomes for patients. DFE Pharma's comprehensive range of lactose-based excipients is designed to offer the right characteristics for the full variety of inhaled medicines in the market. Lactohale(R) 400 is a milled, anhydrous lactose grade suitable for DPI applications requiring good flow and cohesiveness.

Key Segmentation:

Global Pharmaceutical Excipients Market is segmented and analyzed as below:

By Excipient Type

  • Polymers
  • Alcohols
  • Sugars
  • Minerals
  • Others

By Formulation Type

  • Oral
  • Topical
  • Parenteral
  • Others

By Functionality

  • Coating Agents
  • Flavoring Agents & Sweeteners
  • Lubricants & Glidants
  • Colorants
  • Emulsifying Agents
  • Buffering Agents
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Australia
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT TYPE

  • 5.1. Introduction
  • 5.2. Polymers
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Alcohols
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Sugars
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Minerals
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FORMULATION TYPE

  • 6.1. Introduction
  • 6.2. Oral
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Topical
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Parenteral
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FUNCTIONALITY

  • 7.1. Introduction
  • 7.2. Coating Agents
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Flavoring Agents & Sweeteners
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Lubricants & Glidants
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Colorants
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Emulsifying Agents
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness
  • 7.7. Buffering Agents
    • 7.7.1. Market Opportunities and Trends
    • 7.7.2. Growth Prospects
    • 7.7.3. Geographic Lucrativeness
  • 7.8. Others
    • 7.8.1. Market Opportunities and Trends
    • 7.8.2. Growth Prospects
    • 7.8.3. Geographic Lucrativeness

8. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Online
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Offline
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness

9. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Excipient Type
    • 9.2.2. By Formulation Type
    • 9.2.3. By Functionality
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Excipient Type
    • 9.3.2. By Formulation Type
    • 9.3.3. By Functionality
    • 9.3.4. By Distribution Channel
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Excipient Type
    • 9.4.2. By Formulation Type
    • 9.4.3. By Functionality
    • 9.4.4. By Distribution Channel
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Italy
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Spain
        • 9.4.5.5.1. Market Opportunities and Trends
        • 9.4.5.5.2. Growth Prospects
      • 9.4.5.6. Others
        • 9.4.5.6.1. Market Opportunities and Trends
        • 9.4.5.6.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Excipient Type
    • 9.5.2. By Formulation Type
    • 9.5.3. By Functionality
    • 9.5.4. By Distribution Channel
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Israel
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
      • 9.5.5.4. Others
        • 9.5.5.4.1. Market Opportunities and Trends
        • 9.5.5.4.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Excipient Type
    • 9.6.2. By Formulation Type
    • 9.6.3. By Functionality
    • 9.6.4. By Distribution Channel
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Australia
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. India
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Taiwan
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Indonesia
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects
      • 9.6.5.9. Others
        • 9.6.5.9.1. Market Opportunities and Trends
        • 9.6.5.9.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Ashland Global Holdings
  • 11.2. DuPont
  • 11.3. BASF SE
  • 11.4. Roquette Feres
  • 11.5. Evonik Industries AG
  • 11.6. Croda International
  • 11.7. Associated British Foods
  • 11.8. Archer Daniels Midland Company
  • 11.9. Lubrizol Corporation